{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:15:02Z","timestamp":1784546102935,"version":"3.55.0"},"reference-count":104,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Liaoning Provincial Youth Science Foundation, Category B","award":["No. 2025-YQ-10 [Heran Li], China"],"award-info":[{"award-number":["No. 2025-YQ-10 [Heran Li], China"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-11828-5","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T11:00:09Z","timestamp":1777028409000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Role of ferroptosis on immunotherapy in breast cancer"],"prefix":"10.1007","volume":"53","author":[{"given":"Kaiyi","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heran","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"11828_CR1","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/cbf.3676","volume":"40","author":"NT Dastjerd","year":"2022","unstructured":"Dastjerd NT, Valibeik A, Rahimi Monfared S, Goodarzi G, Moradi Sarabi M, Hajabdollahi F, Maniati M, Amri J, Samavarchi Tehrani S (2022) Gene therapy: A promising approach for breast cancer treatment. Cell Biochem Funct 40:28\u201348","journal-title":"Cell Biochem Funct"},{"key":"11828_CR2","first-page":"171","volume":"104","author":"KP Trayes","year":"2021","unstructured":"Trayes KP, Cokenakes SEH (2021) Breast cancer treatment. Am Fam Physician 104:171\u2013178","journal-title":"Am Fam Physician"},{"key":"11828_CR3","doi-asserted-by":"publisher","first-page":"023","DOI":"10.1186\/s12943-023-01805-y","volume":"22","author":"F Ye","year":"2023","unstructured":"Ye F, Dewanjee S, Li Y, Jha NK, Chen ZS, Kumar A, Vishakha T, Behl SK, Jha W, Tang H (2023) Advancements in clinical aspects of targeted therapy and immunotherapy in breast. Mol Cancer 22:023\u201301805","journal-title":"Mol Cancer"},{"key":"11828_CR4","doi-asserted-by":"publisher","first-page":"7517","DOI":"10.3390\/ijms25147517","volume":"25","author":"K Dvir","year":"2024","unstructured":"Dvir K, Giordano S, Leone JP (2024) Immunotherapy in Breast Cancer. Int J Mol Sci 25:7517","journal-title":"Int J Mol Sci"},{"key":"11828_CR5","doi-asserted-by":"publisher","first-page":"S87","DOI":"10.3747\/co.27.5223","volume":"27","author":"K Esfahani","year":"2020","unstructured":"Esfahani K, Roudaia L, Buhlaiga N, Del Rincon SV, Papneja N, Miller WH Jr. (2020) A review of cancer immunotherapy: from the past, to the present, to the future. Curr Oncol 27:S87\u2013S97","journal-title":"Curr Oncol"},{"key":"11828_CR6","doi-asserted-by":"crossref","first-page":"020","DOI":"10.1038\/s41419-019-2210-0","volume":"11","author":"J Li","year":"2020","unstructured":"Li J, Cao F, Yin HL, Huang ZJ, Lin ZT, Mao N, Sun B, Wang G (2020) Ferroptosis: past, present and future. Cell Death Dis 11:020\u20132298","journal-title":"Cell Death Dis"},{"key":"11828_CR7","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","volume":"22","author":"X Jiang","year":"2021","unstructured":"Jiang X, Stockwell BR, Conrad M (2021) Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol 22:266\u2013282","journal-title":"Nat Rev Mol Cell Biol"},{"key":"11828_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2021.107992","volume":"232","author":"S Sui","year":"2022","unstructured":"Sui S, Xu S, Pang D (2022) Emerging role of ferroptosis in breast cancer: new dawn for overcoming tumor. Pharmacol Ther 232:107992","journal-title":"Pharmacol Ther"},{"key":"11828_CR9","first-page":"3532","volume":"12","author":"K Liu","year":"2022","unstructured":"Liu K, Mao X, Li T, Xu Z, An R (2022) Immunotherapy and immunobiomarker in breast cancer: current practice and future. Am J Cancer Res 12:3532\u20133547","journal-title":"Am J Cancer Res"},{"key":"11828_CR10","doi-asserted-by":"publisher","first-page":"175883592513222","DOI":"10.1177\/17588359251322291","volume":"17","author":"Y Xie","year":"2025","unstructured":"Xie Y, Tao Z, Wang B, Zhao Y, Chen X, Li B, Wang J, Chen G et al (2025) Ferroptosis-related genes as prognostic markers for survival and immunotherapy in. Ther Adv Med Oncol 17:17588359251322292","journal-title":"Ther Adv Med Oncol"},{"key":"11828_CR11","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","volume":"56","author":"I Mellman","year":"2023","unstructured":"Mellman I, Chen DS, Powles T, Turley SJ (2023) The cancer-immunity cycle: Indication, genotype, and immunotype. Immunity 56:2188\u20132205","journal-title":"Immunity"},{"key":"11828_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.70333","volume":"14","author":"F Zhan","year":"2026","unstructured":"Zhan F, Hu Y, Jiang X, Fang Z (2026) The progress of ferroptosis of immune cells in the tumor microenvironment and its impact on tumorigenesis and development. Immun Inflamm Dis 14:e70333","journal-title":"Immun Inflamm Dis"},{"key":"11828_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1441338","volume":"14","author":"GL Lupica-Tondo","year":"2024","unstructured":"Lupica-Tondo GL, Arner EN, Mogilenko DA, Voss K (2024) Immunometabolism of ferroptosis in the tumor microenvironment. Front Oncol 14:1441338","journal-title":"Front Oncol"},{"key":"11828_CR14","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.trecan.2023.04.002","volume":"9","author":"SJ Wang","year":"2023","unstructured":"Wang SJ, Dougan SK, Dougan M (2023) Immune mechanisms of toxicity from checkpoint inhibitors. Trends Cancer 9:543\u2013553","journal-title":"Trends Cancer"},{"key":"11828_CR15","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12964-022-00854-y","volume":"20","author":"A Naimi","year":"2022","unstructured":"Naimi A, Mohammed RN, Raji A, Chupradit S, Yumashev AV, Suksatan W, Shalaby MN, Thangavelu L, Kamrava S, Shomali N et al (2022) Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Commun Signal 20:44","journal-title":"Cell Commun Signal"},{"key":"11828_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113365","volume":"143","author":"M Arafat Hossain","year":"2024","unstructured":"Arafat Hossain M (2024) A comprehensive review of immune checkpoint inhibitors for cancer treatment. Int Immunopharmacol 143:113365","journal-title":"Int Immunopharmacol"},{"key":"11828_CR17","first-page":"451","volume":"21","author":"X Kong","year":"2024","unstructured":"Kong X, Zhang J, Chen S, Wang X, Xi Q, Shen H, Zhang R (2024) Immune checkpoint inhibitors: Breakthroughs in cancer treatment. Cancer Biol Med 21:451\u2013472","journal-title":"Cancer Biol Med"},{"key":"11828_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01581-2","volume":"17","author":"W Cheng","year":"2024","unstructured":"Cheng W, Kang K, Zhao A, Wu Y (2024) Dual blockade immunotherapy targeting PD-1\/PD-L1 and CTLA-4 in lung cancer. J Hematol Oncol 17:54","journal-title":"J Hematol Oncol"},{"key":"11828_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00086","volume":"8","author":"JA Seidel","year":"2018","unstructured":"Seidel JA, Otsuka A, Kabashima K (2018) Anti-PD-1 and Anti-CTLA-4 therapies in cancer: Mechanisms of action, efficacy, and limitations. Front Oncol 8:86","journal-title":"Front Oncol"},{"key":"11828_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-025-02822-1","volume":"42","author":"MR Zamani","year":"2025","unstructured":"Zamani MR, \u0160\u00e1cha P (2025) Immune checkpoint inhibitors in cancer therapy: What lies beyond monoclonal antibodies? Med Oncol 42:273","journal-title":"Med Oncol"},{"key":"11828_CR21","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s40487-023-00224-9","volume":"11","author":"P Nunes Filho","year":"2023","unstructured":"Nunes Filho P, Albuquerque C, Pilon Capella M, Debiasi M (2023) Immune checkpoint inhibitors in breast cancer: a narrative review. Oncol Ther 11:171\u2013183 (Id, Orcid,)","journal-title":"Oncol Ther"},{"key":"11828_CR22","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1007\/s12282-021-01247-8","volume":"28","author":"J Zhang","year":"2021","unstructured":"Zhang J, Tian Q, Zhang M, Wang H, Wu L, Yang J (2021) Immune-related biomarkers in triple-negative breast cancer. Breast Cancer 28:792\u2013805 (Id, Orcid,)","journal-title":"Breast Cancer"},{"key":"11828_CR23","doi-asserted-by":"publisher","first-page":"24","DOI":"10.21037\/tbcr-24-21","volume":"5","author":"X Deng","year":"2024","unstructured":"Deng X, Liu J (2024) Narrative review on efficacy and safety of anti-angiogenesis in combination with. Transl Breast Cancer Res 5:24\u201321","journal-title":"Transl Breast Cancer Res"},{"key":"11828_CR24","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1080\/13543784.2022.2054326","volume":"31","author":"C Corti","year":"2022","unstructured":"Corti C, Venetis K, Sajjadi XE, Zattoni L, Curigliano XG et al (2022) CAR-T cell therapy for triple-negative breast cancer and other solid tumors. Expert Opin Investig Drugs 31:593\u2013605","journal-title":"Expert Opin Investig Drugs"},{"key":"11828_CR25","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1093\/jleuko\/qiad144","volume":"115","author":"X Li","year":"2024","unstructured":"Li X, Zhu Y, Yi J, Deng Y, Lei B, Ren H (2024) Adoptive cell immunotherapy for breast cancer: harnessing the power of immune. J Leukoc Biol 115:866\u2013881 (Id, Orcid.)","journal-title":"J Leukoc Biol"},{"key":"11828_CR26","doi-asserted-by":"crossref","first-page":"020","DOI":"10.1038\/s41598-019-56924-8","volume":"10","author":"Z Hu","year":"2020","unstructured":"Hu Z (2020) Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative. Sci Rep 10:020\u201359736","journal-title":"Sci Rep"},{"key":"11828_CR27","doi-asserted-by":"publisher","first-page":"6034","DOI":"10.3390\/cancers14246034","volume":"14","author":"M Luque","year":"2022","unstructured":"Luque M, Sanz-\u00c1lvarez M, Morales-Gallego M, Madoz-G\u00farpide J, Zazo S, Dom\u00ednguez C, Cazorla A, Izarzugaza Y et al (2022) Tumor-Infiltrating Lymphocytes and Immune Response in HER2-Positive Breast. Cancers 14:6034","journal-title":"Cancers"},{"key":"11828_CR28","unstructured":"Li X, Bu X (2017). Progress in Vaccine Therapies for Breast Cancer. Adv Exp Med Biol, 6020\u20136025_6015,"},{"key":"11828_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.828386","volume":"13","author":"SY Zhu","year":"2022","unstructured":"Zhu SY, Yu KD (2022) Breast cancer vaccines: disappointing or promising? Front Immunol 13:828386","journal-title":"Front Immunol"},{"key":"11828_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1052301","volume":"14","author":"L Li","year":"2023","unstructured":"Li L, Duns GJ, Dessie W, Cao Z, Ji X, Luo X (2023) Recent advances in peptide-based therapeutic strategies for breast cancer. Front Pharmacol 14:1052301","journal-title":"Front Pharmacol"},{"key":"11828_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2023.101239","volume":"95","author":"N Gautam","year":"2024","unstructured":"Gautam N, Ramamoorthi G, Champion N, Han HS, Czerniecki BJ (2024) Reviewing the significance of dendritic cell vaccines in interrupting breast. Mol Aspects Med 95:101239","journal-title":"Mol Aspects Med"},{"key":"11828_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2024.06.003","volume":"372","author":"J Mondal","year":"2024","unstructured":"Mondal J, Chakraborty K, Bunggulawa EJ, An JM, Revuri V, Nurunnabi M, Lee YK (2024) Recent advancements of hydrogels in immunotherapy: Breast cancer treatment. J Control Release 372:1\u201330","journal-title":"J Control Release"},{"key":"11828_CR33","doi-asserted-by":"publisher","first-page":"024","DOI":"10.1186\/s13045-024-01564-3","volume":"17","author":"F Chen","year":"2024","unstructured":"Chen F, Kang R, Tang D, Liu J (2024) Ferroptosis: principles and significance in health and disease. J Hematol Oncol 17:024\u201301564","journal-title":"J Hematol Oncol"},{"key":"11828_CR34","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41422-020-00441-1","volume":"31","author":"D Tang","year":"2021","unstructured":"Tang D, Chen X, Kang R, Kroemer G (2021) Ferroptosis: molecular mechanisms and health implications. Cell Res 31:107\u2013125","journal-title":"Cell Res"},{"key":"11828_CR35","doi-asserted-by":"publisher","first-page":"022","DOI":"10.1038\/s41420-022-01212-0","volume":"8","author":"T Ma","year":"2022","unstructured":"Ma T, Du J, Zhang Y, Wang Y, Wang B, Zhang T (2022) GPX4-independent ferroptosis-a new strategy in disease\u2019s therapy. Cell Death Discov 8:022\u201301212","journal-title":"Cell Death Discov"},{"key":"11828_CR36","doi-asserted-by":"publisher","first-page":"116594","DOI":"10.1016\/j.bcp.2024.116594","volume":"230","author":"S Wu","year":"2024","unstructured":"Wu S, Guo N, Xu H, Li Y, Sun T, Jiang X, Fu D, You T, Diao S, Huang Y et al (2024) Caveolin-1 ameliorates hepatic injury in non-alcoholic fatty liver disease by. Biochem Pharmacol 230:116594","journal-title":"Biochem Pharmacol"},{"key":"11828_CR37","doi-asserted-by":"publisher","first-page":"18231","DOI":"10.1111\/jcmm.18231","volume":"28","author":"W Mengjia","year":"2024","unstructured":"Mengjia W, Jun J, Xin Z, Jiahao Z, Jie G (2024) GPX4-mediated bone ferroptosis under mechanical stress decreased bone formation. J Cell Mol Med 28:18231","journal-title":"J Cell Mol Med"},{"key":"11828_CR38","doi-asserted-by":"publisher","first-page":"597434","DOI":"10.3389\/fonc.2020.597434","volume":"10","author":"X Song","year":"2020","unstructured":"Song X, Wang X, Liu Z, Yu Z (2020) Role of GPX4-Mediated Ferroptosis in the Sensitivity of Triple Negative Breast. Front Oncol 10:597434","journal-title":"Front Oncol"},{"key":"11828_CR39","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.freeradbiomed.2020.07.026","volume":"160","author":"T Bai","year":"2020","unstructured":"Bai T, Li M, Liu Y, Qiao Z, Wang Z (2020) Inhibition of ferroptosis alleviates atherosclerosis through attenuating lipid. Free Radic Biol Med 160:92\u2013102","journal-title":"Free Radic Biol Med"},{"key":"11828_CR40","doi-asserted-by":"publisher","first-page":"e520","DOI":"10.1002\/mco2.520","volume":"5","author":"Z Yang","year":"2020","unstructured":"Yang Z, He XY, Wu D, Shi W, Liu P, Tan J, Wang R, Yu B (2020) Antiferroptosis therapy alleviated the development of atherosclerosis. MedComm 5:e520","journal-title":"MedComm"},{"key":"11828_CR41","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3892\/etm.2023.11988","volume":"25","author":"J Xu","year":"2023","unstructured":"Xu J, Han X, Xia N, Zhao Q, Cheng Z (2023) IL-37 suppresses macrophage ferroptosis to attenuate diabetic atherosclerosis via. Exp Ther Med 25:289","journal-title":"Exp Ther Med"},{"key":"11828_CR42","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/s41589-020-0472-6","volume":"16","author":"Y Zou","year":"2020","unstructured":"Zou Y, Li H, Graham ET, Deik AA, Eaton JK, Wang W, Sandoval-Gomez G, Clish CB et al (2020) Cytochrome P450 oxidoreductase contributes to phospholipid peroxidation in. Nat Chem Biol 16:302\u2013309","journal-title":"Nat Chem Biol"},{"key":"11828_CR43","doi-asserted-by":"publisher","first-page":"102923","DOI":"10.1016\/j.redox.2023.102923","volume":"67","author":"L Yao","year":"2023","unstructured":"Yao L, Hou J, Wu X, Lu Y, Jin Z, Yu Z, Yu B, Li J, Yang Z, Li C et al (2023) Cancer-associated fibroblasts impair the cytotoxic function of NK cells in. Redox Biol 67:102923","journal-title":"Redox Biol"},{"key":"11828_CR44","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3233\/CBM-2012-0255","volume":"10","author":"NM Fletcher","year":"2011","unstructured":"Fletcher NM, Jiang Z, Ali-Fehmi R, Levin NK, Belotte J, Tainsky MA, Diamond MP, Abu-Soud HM, Saed GM (2011) Myeloperoxidase and free iron levels: potential biomarkers for early detection. Cancer Biomark 10:267\u2013275","journal-title":"Cancer Biomark"},{"key":"11828_CR45","first-page":"426","volume":"52","author":"T Huang","year":"2022","unstructured":"Huang T, Guan S, Wang C (2022) CERS6-AS1 facilitates oncogenesis and restrains ferroptosis in Papillary Thyroid. Ann Clin Lab Sci 52:426\u2013438","journal-title":"Ann Clin Lab Sci"},{"key":"11828_CR46","doi-asserted-by":"publisher","first-page":"7038","DOI":"10.1111\/febs.16059","volume":"289","author":"J Liu","year":"2022","unstructured":"Liu J, Kang R, Tang D (2022) Signaling pathways and defense mechanisms of ferroptosis. FEBS J 289:7038\u20137050","journal-title":"FEBS J"},{"key":"11828_CR47","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202300881","volume":"10","author":"F Jiang","year":"2023","unstructured":"Jiang F, Jia K, Chen Y, Ji C, Chong X, Li Z, Zhao F, Bai Y, Ge S, Gao J et al (2023) ANO1-Mediated Inhibition of Cancer Ferroptosis Confers Immunotherapeutic Resistance through Recruiting Cancer-Associated Fibroblasts. Adv Sci (Weinh) 10:e2300881","journal-title":"Adv Sci (Weinh)"},{"key":"11828_CR48","first-page":"56834","volume":"15","author":"Y Bao","year":"2023","unstructured":"Bao Y, Li G, Li S, Zhang H, Wu X, Yan R, Wang Z, Guo C, Jin Y (2023) Multifunctional Tumor-Targeting Carbon Dots for Tumor Microenvironment Activated Ferroptosis and Immunotherapy in Cancer Treatment. ACS Appl Mater Interfaces 15:56834\u201356845","journal-title":"ACS Appl Mater Interfaces"},{"key":"11828_CR49","volume":"14","author":"Y Chen","year":"2023","unstructured":"Chen Y, Fang ZM, Yi X, Wei X, Jiang DS (2023) The interaction between ferroptosis and inflammatory signaling pathways. Cell Death Dis 14:023-05716","journal-title":"Cell Death Dis"},{"key":"11828_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s13020-024-00920-2","volume":"19","author":"F Guo","year":"2024","unstructured":"Guo F, Ling G, Qiu J, Li J, Gan Y, Yu Y, Tang J, Mo L, Piao H (2024) Juglone induces ferroptosis in glioblastoma cells by inhibiting the Nrf2-GPX4. Chin Med 19:024-00920","journal-title":"Chin Med"},{"key":"11828_CR51","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2024.151","volume":"8","author":"Y Yang","year":"2025","unstructured":"Yang Y, Yu S, Liu W, Zhuo Y, Qu C, Zeng Y (2025) Ferroptosis-related signaling pathways in cancer drug resistance. Cancer Drug Resist 8:1","journal-title":"Cancer Drug Resist"},{"key":"11828_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01170-9","volume":"21","author":"X Wang","year":"2023","unstructured":"Wang X, Tan X, Zhang J, Wu J, Shi H (2023) The emerging roles of MAPK-AMPK in ferroptosis regulatory network. Cell Commun Signal 21:023-01170","journal-title":"Cell Commun Signal"},{"key":"11828_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1257985","volume":"13","author":"W Mu","year":"2023","unstructured":"Mu W, Zhou Z, Shao L, Wang Q, Feng W, Tang Y, He Y, Wang Y (2023) Advances in the relationship between ferroptosis and epithelial-mesenchymal. Front Oncol 13:1257985","journal-title":"Front Oncol"},{"key":"11828_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2022.188848","volume":"1878","author":"Y Huang","year":"2023","unstructured":"Huang Y, Wang S, Ke A, Guo K (2023) Ferroptosis and its interaction with tumor immune microenvironment in liver cancer. Biochim Biophys Acta Rev Cancer 1878:188848","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"11828_CR55","doi-asserted-by":"publisher","first-page":"4117","DOI":"10.1007\/s10571-023-01399-5","volume":"43","author":"J Chen","year":"2023","unstructured":"Chen J, Chen Z, Yu D, Yan Y, Hao X et al (2023) Neuroprotective Effect of Hydrogen Sulfide Subchronic Treatment Against. Cell Mol Neurobiol 43:4117\u20134140","journal-title":"Cell Mol Neurobiol"},{"key":"11828_CR56","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.cytogfr.2023.08.004","volume":"75","author":"X Zhai","year":"2024","unstructured":"Zhai X, Lin Y, Zhu L, Wang Y, Zhang J, Liu J, Li L, Lu X (2024) Ferroptosis in cancer immunity and immunotherapy: Multifaceted interplay and clinical implications. Cytokine Growth Factor Rev 75:101\u2013109","journal-title":"Cytokine Growth Factor Rev"},{"key":"11828_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2025.103977","volume":"89","author":"W Li","year":"2026","unstructured":"Li W, Tang Z, Xue J (2026) Synergistic STING activation and oxidative cascades-induced ferroptosis drive tumor microenvironment remodeling by engineered manganese nanoreactors. Redox Biol 89:103977","journal-title":"Redox Biol"},{"key":"11828_CR58","doi-asserted-by":"publisher","first-page":"0735","DOI":"10.1126\/science.adu2836","volume":"8","author":"C Zhang","year":"2025","unstructured":"Zhang C, Liu S, Zhang J, Lu J, Chen Z, Pan B, Liu C, Huang M, Zhan H, Wang H et al (2025) A Multifunctional Fe-EGCG@RSL3 Nanomedicine Synergizes Ferroptosis Induction and Tumor Microenvironment Remodeling for Enhanced Bladder Cancer Immunotherapy. Research (Wash DC) 8:0735","journal-title":"Research (Wash DC)"},{"key":"11828_CR59","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41568-022-00459-0","volume":"22","author":"G Lei","year":"2022","unstructured":"Lei G, Zhuang L, Gan B (2022) Targeting ferroptosis as a vulnerability in cancer. Nat Rev Cancer 22:381\u2013396","journal-title":"Nat Rev Cancer"},{"key":"11828_CR60","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1111\/jcmm.17754","volume":"27","author":"CP Li","year":"2023","unstructured":"Li CP, Su HQ, He LP (2023) Vitamin D may alleviate pre-eclampsia by modulating the ferroptosis signalling. J Cell Mol Med 27:1923\u20131927","journal-title":"J Cell Mol Med"},{"key":"11828_CR61","doi-asserted-by":"publisher","DOI":"10.3390\/cells12081128","volume":"12","author":"H Akiyama","year":"2023","unstructured":"Akiyama H, Carter BZ, Andreeff M, Ishizawa J (2023) Molecular mechanisms of ferroptosis and updates of ferroptosis studies in cancers. Cells 12:1128 (Id, Orcid)","journal-title":"Cells"},{"key":"11828_CR62","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-024-02317-5","volume":"41","author":"A Khan","year":"2024","unstructured":"Khan A, Huo Y, Guo Y, Shi J, Hou Y (2024) Ferroptosis is an effective strategy for cancer therapy. Med Oncol 41:024-02317","journal-title":"Med Oncol"},{"key":"11828_CR63","doi-asserted-by":"publisher","first-page":"888570","DOI":"10.3389\/fonc.2022.888570","volume":"12","author":"FM Zhong","year":"2022","unstructured":"Zhong FM, Yao FY, Liu J, Zhang HB, Zhang J, Zhang N, Lin J, Li SQ, Li MY, Jiang JY et al (2022) Ferroptosis-related molecular patterns reveal immune escape, inflammatory. Front Oncol 12:888570","journal-title":"Front Oncol"},{"key":"11828_CR64","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jid.2021.06.014","volume":"142","author":"MF Emmons","year":"2022","unstructured":"Emmons MF, Smalley KSM (2022) Ironing-out the details: New strategies for combining ferroptosis inhibitors with. J Invest Dermatol 142:18\u201320","journal-title":"J Invest Dermatol"},{"key":"11828_CR65","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1016\/j.ccell.2024.10.010","volume":"42","author":"H Lin","year":"2024","unstructured":"Lin H, Tison K, Du Y, Kirchhoff P, Kim C, Wang W, Yang H, Pitter M, Yu J, Liao P et al (2024) Itaconate transporter SLC13A3 impairs tumor immunity via endowing ferroptosis. Cancer Cell 42:2032\u20132044","journal-title":"Cancer Cell"},{"key":"11828_CR66","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1111\/odi.14077","volume":"29","author":"YY Zhao","year":"2023","unstructured":"Zhao YY, Lian JX, Lan Z, Zou KL, Wang WM, Yu GT (2023) Ferroptosis promotes anti-tumor immune response by inducing immunogenic exposure. Oral Dis 29:933\u2013941 (Id, Orcid)","journal-title":"Oral Dis"},{"key":"11828_CR67","doi-asserted-by":"publisher","first-page":"401","DOI":"10.2174\/1566524022666220509124608","volume":"23","author":"J Yin","year":"2023","unstructured":"Yin J, Meng X, Peng L, Xie W, Liu X, He W, Li S (2023) Ferroptosis and cancer immunotherapy. Curr Mol Med 23:401\u2013409","journal-title":"Curr Mol Med"},{"key":"11828_CR68","doi-asserted-by":"publisher","first-page":"022","DOI":"10.1038\/s41420-022-00822-y","volume":"8","author":"D Gong","year":"2022","unstructured":"Gong D, Chen M, Wang Y, Shi J, Hou Y (2022) Role of ferroptosis on tumor progression and immunotherapy. Cell Death Discov 8:022\u201301218","journal-title":"Cell Death Discov"},{"key":"11828_CR69","doi-asserted-by":"publisher","first-page":"e2300230","DOI":"10.1002\/smtd.202300230","volume":"7","author":"H He","year":"2023","unstructured":"He H, Du L, Xue H, An Y, Zeng K, Huang H, He Y, Zhang C, Wu J et al (2023) Triple Tumor Microenvironment-Responsive Ferroptosis Pathways Induced by. Small Methods 7:e2300230","journal-title":"Small Methods"},{"key":"11828_CR70","doi-asserted-by":"publisher","first-page":"e2204514","DOI":"10.1002\/advs.202204514","volume":"10","author":"CH Chung","year":"2023","unstructured":"Chung CH, Lin CY, Chen CY, Hsueh CW, Chang YW, Wang CC, Chu PY, Tai SK, Yang MH et al (2023) Ferroptosis Signature Shapes the Immune Profiles to Enhance the Response to. Adv Sci 10:e2204514","journal-title":"Adv Sci"},{"key":"11828_CR71","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.7150\/ijbs.69808","volume":"18","author":"W Luo","year":"2022","unstructured":"Luo W, Dai W, Li Q, Mo S, Han L, Xiao X, Gu R, Xiang W, Ye L, Wang R et al (2022) Ferroptosis-associated molecular classification characterized by distinct tumor. Int J Biol Sci 18:1773\u20131794","journal-title":"Int J Biol Sci"},{"key":"11828_CR72","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1007\/s10495-024-01988-9","volume":"29","author":"Z Mao","year":"2024","unstructured":"Mao Z, Hu Y, Zhao Y, Zhang X, Guo L, Wang X, Zhang J, Miao M (2024) The mutual regulatory role of ferroptosis and immunotherapy in anti-tumor therapy. Apoptosis 29:1291\u20131308","journal-title":"Apoptosis"},{"key":"11828_CR73","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1038225","volume":"13","author":"X Qi","year":"2022","unstructured":"Qi X, Wan Z, Jiang B, Ouyang Y, Feng W, Zhu H, Tan Y, He R, Xie L, Li Y (2022) Inducing ferroptosis has the potential to overcome therapy resistance in breast. Front Immunol 13:1038225","journal-title":"Front Immunol"},{"key":"11828_CR74","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.actbio.2023.01.022","volume":"159","author":"Y Lin","year":"2023","unstructured":"Lin Y, Chen X, Yu C, Xu G, Nie X, Cheng Y, Luan Y, Song Q (2023) Radiotherapy-mediated redox homeostasis-controllable nanomedicine for enhanced. Acta Biomater 159:300\u2013311","journal-title":"Acta Biomater"},{"key":"11828_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1455741","volume":"15","author":"A Ge","year":"2024","unstructured":"Ge A, Xiang W, Li Y, Zhao D, Chen J, Daga P, Dai CC, Yang K, Yan Y, Hao M, Zhang B, Xiao W (2024) Broadening horizons: the multifaceted role of ferroptosis in breast cancer. Front Immunol 15:1455741","journal-title":"Front Immunol"},{"key":"11828_CR76","doi-asserted-by":"publisher","first-page":"025","DOI":"10.1038\/s41419-025-07354-0","volume":"16","author":"J Cao","year":"2025","unstructured":"Cao J, Zhou T, Wu T, Lin R, Huang J, Shi D, Yu J, Ren Y, Qian C et al (2025) Targeting estrogen-regulated system x(c)(-) promotes ferroptosis and endocrine. Cell Death Dis 16:025\u201307354","journal-title":"Cell Death Dis"},{"key":"11828_CR77","doi-asserted-by":"crossref","unstructured":"Sui S, Xu S, Pang D (2022). Emerging role of ferroptosis in breast cancer: New dawn for overcoming tumor. Pharmacol Ther 232","DOI":"10.1016\/j.pharmthera.2021.107992"},{"key":"11828_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2023.113737","volume":"431","author":"X Huang","year":"2023","unstructured":"Huang X, Wu J, Wang Y, Xian Z, Li J, Qiu N, Li H (2023) FOXQ1 inhibits breast cancer ferroptosis and progression via the. Exp Cell Res 431:113737","journal-title":"Exp Cell Res"},{"key":"11828_CR79","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.15060","volume":"17","author":"C Yi","year":"2023","unstructured":"Yi C, Wu S, Duan Q, Liu L, Li L, Luo Y, Wang A (2023) Ferroptosis-dependent breast cancer cell-derived exosomes inhibit migration and. PeerJ 17:e15060","journal-title":"PeerJ"},{"key":"11828_CR80","doi-asserted-by":"publisher","DOI":"10.21037\/atm-22-3736","volume":"10","author":"Z He","year":"2022","unstructured":"He Z, Zhou Z, Wang F, Gai L, Huang Y, Zhong X, Li J, Zuo L, Zhang N, Ni S (2022) Comprehensive analysis of the relationship between the ferroptosis and. Ann Transl Med 10:22-3736","journal-title":"Ann Transl Med"},{"key":"11828_CR81","first-page":"3985","volume":"11","author":"F Bakar-Ates","year":"2024","unstructured":"Bakar-Ates F, Ozkan E (2024) Synergistic ferroptosis in triple-negative breast cancer cells: Paclitaxel in. Naunyn Schmiedebergs Arch Pharmacol 11:3985\u20133994","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"11828_CR82","doi-asserted-by":"publisher","first-page":"023","DOI":"10.1038\/s41419-023-06042-1","volume":"14","author":"SY Park","year":"2023","unstructured":"Park SY, Jeong KJ, Poire A, Zhang D, Tsang YH, Blucher AS, Mills GB et al (2023) Irreversible HER2 inhibitors overcome resistance to the RSL3 ferroptosis inducer. Cell Death Dis 14:023\u201306042","journal-title":"Cell Death Dis"},{"key":"11828_CR83","doi-asserted-by":"publisher","first-page":"7213","DOI":"10.1007\/s00210-024-03049-z","volume":"397","author":"E Heydarnia","year":"2024","unstructured":"Heydarnia E, Sepasi A, Asefi N, Khakshournia S, Mohammadnejad J (2024) The effects of metformin and PCL-sorafenib nanoparticle co-treatment on MCF-7. Naunyn Schmiedebergs Arch Pharmacol 397:7213\u20137221","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"11828_CR84","doi-asserted-by":"publisher","DOI":"10.1186\/s11671-021-03497-z","volume":"16","author":"Z Li","year":"2021","unstructured":"Li Z, Wu X, Wang W, Gai C, Zhang W, Li W, Ding D (2021) Fe(II) and tannic acid-cloaked MOF as carrier of artemisinin for supply of. Nanoscale Res Lett 16:021-03497 (Id, Orcid)","journal-title":"Nanoscale Res Lett"},{"key":"11828_CR85","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-021-01058-1","volume":"19","author":"X Yao","year":"2021","unstructured":"Yao X, Xie R, Cao Y, Tang J, Men Y, Peng H, Yang W (2021) Simvastatin induced ferroptosis for triple-negative breast cancer therapy. J Nanobiotechnol 19:021-01058 (Id, Orcid)","journal-title":"J Nanobiotechnol"},{"key":"11828_CR86","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.1111\/cas.14181","volume":"110","author":"M Yu","year":"2019","unstructured":"Yu M, Gai C, Li Z, Ding D, Zheng J, Zhang W, Lv S, Li W (2019) Targeted exosome-encapsulated erastin induced ferroptosis in triple negative. Cancer Sci 110:3173\u20133182","journal-title":"Cancer Sci"},{"key":"11828_CR87","doi-asserted-by":"publisher","first-page":"10446","DOI":"10.18632\/aging.205940","volume":"16","author":"W Li","year":"2024","unstructured":"Li W, Guo Y, Xu Z, Li F, Dong Y, Xu F (2024) Notoginsenoside R1 (NGR1) regulates the AGE-RAGE signaling pathway by inhibiting. Aging 16:10446\u201310461","journal-title":"Aging"},{"key":"11828_CR88","first-page":"497","volume":"16","author":"QE Wen","year":"2024","unstructured":"Wen QE, Li L, Feng RQ, Li DH, Qiao C, Xu XS, Zhang YJ (2024) Recent advances in immunotherapy for breast cancer: A review. Breast Cancer 16:497\u2013516","journal-title":"Breast Cancer"},{"key":"11828_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2023.101817","volume":"39","author":"S Xu","year":"2024","unstructured":"Xu S, Tuo QZ, Meng J, Wu XL, Li CL, Lei P (2024) Thrombin induces ferroptosis in triple-negative breast cancer through the. Transl Oncol 39:101817","journal-title":"Transl Oncol"},{"key":"11828_CR90","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.7150\/ijbs.82120","volume":"19","author":"YM Chen","year":"2023","unstructured":"Chen YM, Xu W, Liu Y, Zhang JH, Yang YY, Wang ZW, Sun DJ, Li H, Liu B, Chen LX (2023) Anomanolide C suppresses tumor progression and metastasis by ubiquitinating. Int J Biol Sci 19:2531\u20132550","journal-title":"Int J Biol Sci"},{"key":"11828_CR91","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17050739","volume":"17","author":"J Xu","year":"2025","unstructured":"Xu J, Bai X, Dong K, Du Q, Ma P, Zhang Z, Yang J (2025) GluOC induced SLC7A11 and SLC38A1 to activate redox processes and resist. Cancers 17:739","journal-title":"Cancers"},{"key":"11828_CR92","doi-asserted-by":"publisher","first-page":"175883592513222","DOI":"10.1177\/17588359251322291","volume":"17","author":"Y Xie","year":"2025","unstructured":"Xie Y, Tao Z, Wang B, Zhao Y, Chen X, Li B, Wang J, Chen G, Hu X (2025) Ferroptosis-related genes as prognostic markers for survival and immunotherapy in triple-negative breast cancer: analysis of public databases and a single institution. Ther Adv Med Oncol 17:17588359251322292","journal-title":"Ther Adv Med Oncol"},{"key":"11828_CR93","doi-asserted-by":"publisher","first-page":"e24094","DOI":"10.1002\/jcla.24094","volume":"35","author":"LY Jin","year":"2021","unstructured":"Jin LY, Gu YL, Zhu Q, Li XH, Jiang GQ (2021) The role of ferroptosis-related genes for overall survival prediction in breast. J Clin Lab Anal 35:e24094","journal-title":"J Clin Lab Anal"},{"key":"11828_CR94","doi-asserted-by":"publisher","first-page":"025","DOI":"10.1186\/s12967-025-07498-9","volume":"23","author":"X Zhu","year":"2025","unstructured":"Zhu X, Lu H, Jia H, Wei X, Xue J, Li W, Zhang J, Wang Y, Yan J, Sun H et al (2025) Ferrostatin-1 reduces the inflammatory response of rheumatoid arthritis by. J Transl Med 23:025\u201306300","journal-title":"J Transl Med"},{"key":"11828_CR95","doi-asserted-by":"publisher","first-page":"5883","DOI":"10.7150\/thno.99303","volume":"14","author":"T Han","year":"2024","unstructured":"Han T, Sun Y, Jiang X, Gong C, Kong F, Luo Y, Ge C, Liu C, Liu Y, Mou Y et al (2024) Air bag-embedded MIL-101(Fe) metal-organic frameworks for an amplified tumor. Theranostics 14:5883\u20135902","journal-title":"Theranostics"},{"key":"11828_CR96","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s10495-021-01663-3","volume":"26","author":"A Murao","year":"2021","unstructured":"Murao A, Aziz M, Wang H, Brenner M, Wang P (2021) - Release mechanisms of major DAMPs. Apoptosis 26:152\u2013162 (Id- Orcid, X.)","journal-title":"Apoptosis"},{"key":"11828_CR97","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ncrna.2025.06.002","volume":"14","author":"JN Zhang","year":"2025","unstructured":"Zhang JN, Yi ZL, Zhou XR, Liu SS, Liu H (2025) Dual role of lncRNA OTUD6B-AS1 in immune evasion and ferroptosis resistance: A prognostic and therapeutic biomarker in breast cancer. Noncoding RNA Res 14:156\u2013165","journal-title":"Noncoding RNA Res"},{"key":"11828_CR98","volume":"15","author":"C Gao","year":"2024","unstructured":"Gao C, Zhang H, Wang X (2024) Current advances on the role of ferroptosis in tumor immune evasion. Discov Oncol 15:024-01573","journal-title":"Discov Oncol"},{"key":"11828_CR99","doi-asserted-by":"publisher","DOI":"10.31083\/j.fbl2707203","volume":"27","author":"Z Zhou","year":"2022","unstructured":"Zhou Z, Xu B, Hu N, Guo Z, Bao W, Shao B, Yang W (2022) Targeting the macrophage-ferroptosis crosstalk: a novel insight into tumor. Front Biosci 27:203","journal-title":"Front Biosci"},{"key":"11828_CR100","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1019654","volume":"12","author":"T Yun","year":"2022","unstructured":"Yun T, Liu Z, Wang J, Wang R, Zhu L, Zhu Z, Wang X (2022) Microenvironment immune response induced by tumor ferroptosis-the application of. Front Oncol 12:1019654","journal-title":"Front Oncol"},{"key":"11828_CR101","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1136\/jitc-2023-006890","volume":"11","author":"Z Wang","year":"2023","unstructured":"Wang Z, Li R, Hou N, Zhang J, Wang T, Fan P, Ji C, Zhang B, Liu L et al (2023) PRMT5 reduces immunotherapy efficacy in triple-negative breast cancer by. J Immunother Cancer 11:2023\u2013006890","journal-title":"J Immunother Cancer"},{"key":"11828_CR102","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1080\/17425247.2024.2379937","volume":"21","author":"H Zhou","year":"2024","unstructured":"Zhou H, Cheng Y, Huang Q, Xiao J (2024) Regulation of ferroptosis by nanotechnology for enhanced cancer immunotherapy. Expert Opin Drug Deliv 21:921\u2013943","journal-title":"Expert Opin Drug Deliv"},{"key":"11828_CR103","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23179767","volume":"23","author":"X Xu","year":"2022","unstructured":"Xu X, Zhou N, Lan H, Yang F, Dong B, Zhang X (2022) The ferroptosis molecular subtype reveals characteristics of the tumor. Int J Mol Sci 23:9767","journal-title":"Int J Mol Sci"},{"key":"11828_CR104","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1119369","volume":"13","author":"H Cai","year":"2023","unstructured":"Cai H, Ren Y, Chen S, Wang Y, Chu L (2023) Ferroptosis and tumor immunotherapy: a promising combination therapy for tumors. Front Oncol 13:1119369","journal-title":"Front Oncol"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11828-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-11828-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11828-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T12:02:49Z","timestamp":1777032169000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-11828-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":104,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["11828"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-11828-5","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"assertion":[{"value":"1 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"655"}}